Literature DB >> 30964947

Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.

Anna C Van der Vossen1, Lidwien M Hanff2, Arnold G Vulto1, Nikoletta Fotaki3.   

Abstract

AIMS: This study explores the impact of paediatric patient related factors and choice of formulation on the dissolution characteristics of nifedipine and lorazepam, 2 drug substances regularly applied in very young patients and in compounded formulations.
METHODS: Dissolution experiments were designed to reflect clinical practice in a paediatric hospital, with respect to dosage forms, feeding regimens and methods of administration. Solubility studies addressed the influence of age and prandial state. Drug solubility and dissolution experiments were conducted in biorelevant media and adapted age-specific (neonate and infant) media. Dissolution studies were performed with the mini-paddle apparatus and the flow-through cell apparatus.
RESULTS: Dissolution of nifedipine formulations was not affected by age-related changes of the fasted state simulated gastrointestinal fluids, and by disintegration of the formulation before administration. However, a significant difference in nifedipine's dissolution rate from commercial tablets and compounded capsules was observed. The dissolution of lorazepam tablets was affected by fasted- vs fed-state media, but it was deemed less likely to be clinically relevant. The significant effect of fed-state media on nifedipine's solubility was considered to have possible clinical relevance since very young patients are almost continuously in a fed state.
CONCLUSION: The in vitro results obtained from these studies reveal the potential of biorelevant solubility and dissolution studies reflecting clinical practice to predict drug performance in paediatric patients.
© 2019 The British Pharmacological Society.

Entities:  

Keywords:  biorelevant; dissolution; lorazepam; nifedipine; paediatric; solubility

Mesh:

Substances:

Year:  2019        PMID: 30964947      PMCID: PMC6624402          DOI: 10.1111/bcp.13956

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.

Authors:  Anna C Van der Vossen; Lidwien M Hanff; Arnold G Vulto; Nikoletta Fotaki
Journal:  Br J Clin Pharmacol       Date:  2019-06-18       Impact factor: 4.335

2.  Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds.

Authors:  Maria Vertzoni; Jennifer Dressman; James Butler; John Hempenstall; Christos Reppas
Journal:  Eur J Pharm Biopharm       Date:  2005-08       Impact factor: 5.571

3.  Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug.

Authors:  A C van der Vossen; I van der Velde; O S N M Smeets; D J Postma; M Eckhardt; A Vermes; B C P Koch; A G Vulto; L M Hanff
Journal:  Eur J Pharm Sci       Date:  2017-01-23       Impact factor: 4.384

4.  In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context.

Authors:  H Lennernäs; A Lindahl; A Van Peer; C Ollier; T Flanagan; R Lionberger; A Nordmark; S Yamashita; L Yu; G L Amidon; V Fischer; E Sjögren; P Zane; M McAllister; B Abrahamsson
Journal:  Mol Pharm       Date:  2017-03-01       Impact factor: 4.939

5.  [Studies of novel 1,4-dihydropyridine Ca antagonist CS-905. I. Measurement of partition coefficient (log P) by high performance liquid chromatography (HPLC)].

Authors:  K Masumoto; A Takeyasu; K Oizumi; T Kobayashi
Journal:  Yakugaku Zasshi       Date:  1995-03       Impact factor: 0.302

6.  Evaluation of the safety of short-acting nifedipine in children with hypertension.

Authors:  David W Egger; Douglas D Deming; Norman Hamada; Ronald M Perkin; Shobha Sahney
Journal:  Pediatr Nephrol       Date:  2002-01       Impact factor: 3.714

7.  Simulating Different Dosing Scenarios for a Child-Appropriate Valproate ER Formulation in a New Pediatric Two-Stage Dissolution Model.

Authors:  Frank Karkossa; Antonia Krueger; Jana Urbaniak; Sandra Klein
Journal:  AAPS PharmSciTech       Date:  2016-12-01       Impact factor: 3.246

8.  Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs.

Authors:  E Galia; E Nicolaides; D Hörter; R Löbenberg; C Reppas; J B Dressman
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

9.  The importance of drug ionization for the action of calcium-antagonists and related compounds.

Authors:  R Mannhold; R Rodenkirchen; R Bayer; W Haas
Journal:  Arzneimittelforschung       Date:  1984

10.  Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine.

Authors:  H Bode; E Brendel; G Ahr; U Fuhr; S Harder; A H Staib
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

View more
  4 in total

1.  Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.

Authors:  Anna C Van der Vossen; Lidwien M Hanff; Arnold G Vulto; Nikoletta Fotaki
Journal:  Br J Clin Pharmacol       Date:  2019-06-18       Impact factor: 4.335

2.  Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.

Authors:  Mariana Guimarães; Maria Vertzoni; Nikoletta Fotaki
Journal:  AAPS J       Date:  2022-01-10       Impact factor: 4.009

3.  Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.

Authors:  Mariana Guimarães; Pascal Somville; Maria Vertzoni; Nikoletta Fotaki
Journal:  AAPS J       Date:  2022-01-10       Impact factor: 4.009

4.  Development of an Age-Appropriate Mini Orally Disintegrating Carvedilol Tablet with Paediatric Biopharmaceutical Considerations.

Authors:  Dilawar Khan; Daniel Kirby; Simon Bryson; Maryam Shah; Afzal Rahman Mohammed
Journal:  Pharmaceutics       Date:  2021-06-03       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.